ReviewJournal of medicinal chemistry2026
Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration.
Review in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kinases represent one of the main targets of interest in recent years, completely revolutionizing small molecule anticancer therapy. Particularly, several medicinal chemistry strategies (e.g., covalent and allosteric inhibitors) allowed overcoming of the challenging selectivity issue, thus enabling the massive clinical translation of kinase inhibitors. However, the same success has not been detected yet for tackling neurodegenerative diseases, despite plenty of experimental evidence regarding kinases' pivotal roles in onset and development of neurodegenerative processes. In this perspective we highlight the therapeutic potential of allosteric kinase modulators in this respect, by showcasing the developmental processes and neuroprotective properties of CNS-directed allosteric kinases modulators developed so far. Moreover, we present additional kinases whose modulation is related to neuroprotection and featured by validated allosteric modulators not yet exploited in this context. This, along with a critical discussion on main drawbacks and future directions, may foster the development of allosteric kinase modulators in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.